Management of osteosarcoma with Rizzoli therapy in routine services in a developing country

Authors

  • Natalia Arango Instituto Nacional de Cancerología
  • Carlos Bonilla Instituto Nacional de Cancerología
  • Ricardo Sánchez Instituto Nacional de Cancerología

Keywords:

Osteosarcoma, Chemotherapy, Amputation, Limb salvage
Abstract Authors References How to Cite

Abstract

Objective: To describe the clinical and epidemiological characteristics of patients with osteosarcoma high grade limb osteosarcoma treated between 2007 and 2010 using Rizzoli 2 or Rizzoli 4 protocols in the National Cancer Institute, Colombia.
Materials and methods: An analysis was made of the medical histories of patients with limb osteosarcoma who had received treatment with the Rizzoli 2 or Rizzoli 4 protocol. Descriptive statistics were used and survival and recurrence rates were estimated.
Results: A total of 18 patients were found that had received treatment using the Rizzoli protocol. The mean age was 25 years (SD=10.2) and the most frequent anatomical location was in the femur. Surgery was performed on 15 of the 18 patients who received pre-operative chemotherapy, with limb salvage being achieved in 9 (60%) of them, and the remainder required amputation. A good pathological response was observed in the 15 patients who received surgery (tumor viability ≤ 10%) in 5 (33.33%). In the follow up at 2 years, 57% of the patients were still alive. The most frequent non-hematological adverse event was a grade 3 increase in transaminases. The most frequent hematology event was grade 2 leukopenia and grade 3 neutropenia
Of the 18 patients, 7 of them dropped out of the treatment (2 during neoadjuvant and 5 during adjuvant).
Conclusions: The use of the Rizzoli 2 and 4 protocols in this population gave lower response, limb salvage, and overall survival rates than those reported in other publications.

Author Biographies

Natalia Arango, Instituto Nacional de Cancerología

Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Universidad El Bosque, Bogotá D.C., Colombia

Carlos Bonilla, Instituto Nacional de Cancerología

Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Universidad El Bosque, Bogotá D.C., Colombia

Ricardo Sánchez, Instituto Nacional de Cancerología

Grupo de Epidemiología Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia

References

Picci P. Osteosarcoma (Osteogenic Sarcoma) - A Review. Orphan J Rare Dis. 2007;2:6-9.

https://doi.org/10.1186/1750-1172-2-6

Mirabello L, Troisi RJ, Savage SA. Osteosarcoma Incidence and Survival Rates From 1973 to 2004. Data From the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531-43.

https://doi.org/10.1002/cncr.24121

Jemal A, Siegel R, Ward E, Yongping Hao, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.

https://doi.org/10.3322/caac.20006

Malawer MM, Helman LJ, O'Sullivan B. Chapter 45, Section 2: Sarcomas of Bone. En: De Vita VT, Lawrence TS, Rosenberg SA, editores. Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology. 8th edition Lippincott Williams & Wilkins Publishers; 2008.

Klein MJ, Siegal GP. Osteosrcoma. Anatomic and Histologic Variants. Am J Clin Pathol. 2006;125:555-81.

https://doi.org/10.1309/UC6KQHLD9LV2KENN

Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-20.

https://doi.org/10.1097/00003086-198011000-00013

Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am. 1996;27(3):473-81.

Edge SB, Byrd DR, Compton CC, et al., eds.: Bone. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010, p. 281-90.

Ta HT, Dass CR, Choong PFM, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247-63.

https://doi.org/10.1007/s10555-009-9186-7

Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute. Italy Eur J Cancer. 2005;41:2836-45.

Marulanda GA, Henderson ER, Johnson DA, Letson GD, Cheong D. Orthopedic Surgery Options for the Treatment or Primary Osteosarcoma. Cancer Control. 2008;15(1):13-20.

https://doi.org/10.1177/107327480801500103

Johansen R, Nielsen OS, Keller J. Functional outcome in sarcomas treated with limb salvage surgery or amputation. Sarcoma. 1998;2:19-23.

Asknes LH, Bauer HC, Jebsen NL, Folleras G, Allert C, Haugen GS, et al. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008;90(6):786-94.

https://doi.org/10.1302/0301-620X.90B6.19805

Yonemoto T, Ishii T, Takeuchi Y, Kimura K, Hagiwara Y, Iwata S, et al. Evaluation of quality of life (QOL) in long-term survivors of high-grade osteosarcoma: a Japanese single center experience. Anticancer Res. 2007;27(5B):3621-4.

https://doi.org/10.1159/000113038

Eiser C, Darlington AS, Stride CB, Grimer R. Quality of life implications as a consequence of surgery: limb salvage, primary and secondary amputation. Sarcoma. 2001;5(4):189-95.

https://doi.org/10.1080/13577140120099173

Marina N, Gebharrdt M, Teot L, Gorlick R. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist. 2004;9:422-41.

https://doi.org/10.1634/theoncologist.9-4-422

Whelan JS, Burcombe RJ, Janinis J, Baldelli AM, Cassoni AM. A systematic review of pulmonary irradiation in the management of primary bone tumours. Ann Oncol. 2002;13:23-30.

https://doi.org/10.1093/annonc/mdf047

Claude L, Rousmans S, Carrie C, Breteau N, Dijoud F, Gentet JC, et al. Standards and Options for the use of radiation therapy in the management of patients with osteosarcoma. Update 2004. Cancer Radiother. 2005;9(2):104-21.

Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009;10(1-2):82-93.

Bramwell VH, Burgers M, Snearh R, Souhami R, Van Oosterom AT, Voute PA, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosracoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-91.

https://doi.org/10.1200/JCO.1992.10.10.1579

Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101(1):14-8.

Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy: Study COSS 80. J Cancer Res Clin Oncol. 1983;106:21-4.

https://doi.org/10.1007/BF00625047

Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: Regional mapping of viable and non-viable tumor. Cancer. 1985;56:1515-21.

https://doi.org/10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated in a single institution. Cancer. 2006;106(5):1154-61.

https://doi.org/10.1002/cncr.21724

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol. 2002;20(3):776-90.

https://doi.org/10.1200/JCO.20.3.776

Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto Al, Jesus-Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006;24(7):1161-8.

https://doi.org/10.1200/JCO.2005.03.5352

Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA. Prognostic factors and outcomes for osteosarcoma: An international colla boration. Eur J Cancer. 2009;45:2367-75.

https://doi.org/10.1016/j.ejca.2009.03.005

Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-Term Outcome for Patients With Nonmetastatic Osteosrcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli Accodding to the Istituto Ortopedico rizzoli/osteosarcoma- 2 Protocol: An Updated Report. J Clin Oncol. 2000;18: 4016-27.

https://doi.org/10.1200/JCO.2000.18.24.4016

Bacci G, Briccoli A, Ferrari S, Longhi A, Mercui M, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001;37:2030-9.

https://doi.org/10.1016/S0959-8049(01)00229-5

National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Bethesda, Md: U.S. Department of Health and Human Services, National Institutes of Health, 2003. Disponible en línea en: http://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/ctcaev3.pdf Accesado por última vez en octubre de 2013.

Benjamin RS, Patel SR. Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res. 2010;152:355-63.

https://doi.org/10.1007/978-1-4419-0284-9_19

Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol. 2013;31(18):2303-12.

https://doi.org/10.1200/JCO.2012.43.8598

Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J chemother. 2009;21(2):205-10.

https://doi.org/10.1179/joc.2009.21.2.205

Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin and doxorubicina with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clinic Oncol. 2012;30:2112-8.

https://doi.org/10.1200/JCO.2011.38.4420

Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, et al. International colla boration is feasible in trial for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339-53.

https://doi.org/10.1007/978-1-4419-0284-9_18

EURAMOS. http://www.ctu.mrc.ac.uk/euramos/. Accesado en octubre de 2013. Tipo de referencia.

EURAMOS-1 study: recruitment, characteristics, and initial treatment of more than 2000 patients (pts) with high-grade osteosarcoma. J Clin Oncol. 2012; 30.(suppl; abstr 10081).

Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, et al. Chemotherapeutoic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431-45.

https://doi.org/10.1016/j.ejca.2011.05.030

Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatments - Where do we stand? A state of the art review. Cancer Treat Rev. 2013:27.

How to Cite

[1]
Arango, N. et al. 2014. Management of osteosarcoma with Rizzoli therapy in routine services in a developing country. Revista Colombiana de Cancerología. 18, 2 (Jun. 2014), 69–77.

Downloads

Download data is not yet available.

Downloads

Published

2014-06-01

Issue

Vol. 18 No. 2 (2014)

Section

Research/original articles

License

Todos los derechos reservados. 

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views